Skip to search formSkip to main contentSkip to account menu

autologous tumor cell vaccine

Known as: AC vaccine, ATCV, Autologous Cell Vaccine 
A therapeutic agent produced by isolating tumor cells from an individual and processing these tumor cells into a vaccine formulation in vitro; the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
A xenogeneic melanoma-antigen-enhanced allogeneic tumor cell vaccine (ATCV) is an appealing strategy for anti-cancer… 
Highly Cited
2005
Highly Cited
2005
Purpose: Human CD40 ligand activates the malignant B-cell chronic lymphocytic leukemia cells and enhances their capacity to… 
Highly Cited
2004
Highly Cited
2004
For active specific immunotherapy of cancer patients, we designed the autologous virus–modified tumor cell vaccine ATV-NDV. The… 
Highly Cited
2004
Highly Cited
2004
Prognosis of patients with advanced head and neck squamous cell carcinomas (HNSCC) is still poor. Therefore, we analyzed whether… 
Highly Cited
2003
Highly Cited
2003
AIM To treat patients with stage I-IV malignant tumors of digestive tract using autologous tumor cell vaccine and NDV (Newcastle… 
Highly Cited
2000
Highly Cited
2000
PURPOSE A randomized phase III clinical trial of adjuvant active specific immunotherapy (ASI) with an autologous tumor cell… 
Highly Cited
1996
Highly Cited
1995
Highly Cited
1995
BACKGROUND Cancer cells of microscopic metastases can be envisaged as ideal constituents for the development of a genetically… 
Highly Cited
1993
Highly Cited
1993
Summary For active specific immunotherapy, autologous tumor cells grown in vitro may be a more appropriate source of tumor… 
Highly Cited
1991
Highly Cited
1991
Twenty-four patients with metastatic melanoma were treated with a novel form of active immunotherapy, autologous tumor cell…